

ADMA BIOLOGICS, INC.  
Form 8-K  
October 03, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 27, 2018

**ADMA BIOLOGICS, INC.**

(Exact name of registrant as specified in its charter)

Delaware                      001-36728    56-2590442  
(State or other jurisdiction (Commission (IRS Employer

of incorporation)              File Number) Identification No.)

465 State Route 17, Ramsey, New              07446  
Jersey  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

“ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

“ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 27, 2018, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) approved payments in 2019 of the following temporary living expenses of certain of the Company’s named executive officers: (i) a continuation payment of \$5,000 per month in temporary housing expenses, plus appropriate tax gross-up, through December 2019, for Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer; and (ii) a continuation payment of \$8,000 per month in temporary living expenses, plus appropriate tax gross-up, through December 2019, for Dr. James Mond, the Company’s Executive Vice President, Chief Scientific Officer and Chief Medical Officer. As previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on February 15, 2018, the Board previously approved the temporary housing expense payments of \$5,000 and \$8,000 to Mr. Lenz and Dr. Mond, respectively, plus appropriate tax gross-ups, through December 2018.

**Item 8.01**

**Other Events.**

On October 3, 2018, the Company issued a press release announcing that its wholly-owned subsidiary, ADMA Bio Centers Georgia Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its third plasma collection center, located at 166 Ernest W Barrett Parkway, NW, Marietta, Georgia. The facility commenced operations and initiated source plasma collection in December 2017, and is now FDA licensed to collect and enter into interstate commerce to sell and use the human source plasma for further manufacturing in the United States.

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01**

**Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No. Description

99.1 ADMA Biologics, Inc. Press Release, dated October 3, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 3, 2018 ADMA Biologics, Inc.

By: /s/ Brian Lenz

Name: Brian Lenz

Title: Executive Vice President and Chief Financial Officer